Disclosures for "LIBRA Study: Design of an enriched randomized withdrawal, placebo-controlled, Phase 2/3 trial of basimglurant, a first-in-class mGluR5 NAM, to treat pain associated with Trigeminal Neuralgia"
-
Dr. Tahiri has received personal compensation for serving as an employee of Noema Pharma.
-
Dr. Garibaldi has nothing to disclose.
-
Dr. Terrill has nothing to disclose.
-
Dr. Lasser has received personal compensation for serving as an employee of Noema Pharma.
-
Dr. Knappertz has received personal compensation for serving as an employee of Noema Pharmaceuticals . Dr. Knappertz has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of Prof. Zakrzewska has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Noema. The institution of Prof. Zakrzewska has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Noema. The institution of Prof. Zakrzewska has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Kriya. The institution of Prof. Zakrzewska has received research support from British Pain Society . The institution of Prof. Zakrzewska has received research support from LifeArc. Prof. Zakrzewska has received publishing royalties from a publication relating to health care.